Data / Form D filings / Theraclone Sciences, Inc.
Theraclone Sciences, Inc.: Form D filings
Theraclone Sciences, Inc., a biotechnology company in Seattle, WA, filed 7 Form D notices with the SEC between 2010 and 2015. The latest, on May 7, 2015, reports $3.1 million sold of a $4.4 million offering to 12 investors.
Find out what Theraclone Sciences, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1124 COLUMBIA ST, SUITE 300, Seattle, WA, 98104
- Phone
- (206) 805-1617
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1310967
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 7, 2015 | New notice | $4,408,149 | $3,080,000 | $1,328,149 | 12 | Apr 24, 2015 | sec.gov |
| Jul 29, 2013 | Amendment | $6,396,000 | $6,000,000 | $396,000 | 2 | Mar 11, 2013 | sec.gov |
| Jul 29, 2013 | New notice | $6,396,000 | $6,000,000 | $396,000 | 2 | Mar 11, 2013 | sec.gov |
| Mar 26, 2013 | New notice | $8,000,001 | $4,000,000 | $4,000,001 | 18 | Mar 11, 2013 | sec.gov |
| Nov 23, 2011 | Amendment | $11,584,603 | $11,584,603 | $0 | 13 | Aug 30, 2011 | sec.gov |
| Sep 12, 2011 | New notice | $10,584,603 | $10,584,603 | $0 | 12 | Aug 30, 2011 | sec.gov |
| Mar 17, 2010 | New notice | $1,500,000 | $1,500,000 | $0 | 1 | Mar 17, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Steven Gillis | Executive Officer, Director | |
| Kristine Swiderek | Executive Officer | |
| Wende Hutton | Director | |
| Russ Hawkinson | Executive Officer | |
| Wendye Robbins | Director | |
| Clifford Stocks | Executive Officer, Director | |
| Christopher Mirabelli | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of May 4, 2015 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Theraclone Sciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.